rs2043691
Positions:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_000137.4(FAH):c.961-35C>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.642 in 1,536,806 control chromosomes in the GnomAD database, including 320,385 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.62 ( 29395 hom., cov: 32)
Exomes 𝑓: 0.64 ( 290990 hom. )
Consequence
FAH
NM_000137.4 intron
NM_000137.4 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -1.01
Genes affected
FAH (HGNC:3579): (fumarylacetoacetate hydrolase) Predicted to enable fumarylacetoacetase activity. Predicted to be involved in L-phenylalanine catabolic process; homogentisate catabolic process; and tyrosine catabolic process. Predicted to act upstream of or within arginine catabolic process. Located in extracellular exosome. Implicated in tyrosinemia type I. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.87).
BP6
Variant 15-80180089-C-A is Benign according to our data. Variant chr15-80180089-C-A is described in ClinVar as [Benign]. Clinvar id is 255284.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.833 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FAH | NM_000137.4 | c.961-35C>A | intron_variant | ENST00000561421.6 | NP_000128.1 | |||
FAH | NM_001374377.1 | c.961-35C>A | intron_variant | NP_001361306.1 | ||||
FAH | NM_001374380.1 | c.961-35C>A | intron_variant | NP_001361309.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FAH | ENST00000561421.6 | c.961-35C>A | intron_variant | 1 | NM_000137.4 | ENSP00000453347 | P1 |
Frequencies
GnomAD3 genomes AF: 0.618 AC: 93868AN: 151892Hom.: 29378 Cov.: 32
GnomAD3 genomes
AF:
AC:
93868
AN:
151892
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.646 AC: 154919AN: 239904Hom.: 50980 AF XY: 0.656 AC XY: 85580AN XY: 130476
GnomAD3 exomes
AF:
AC:
154919
AN:
239904
Hom.:
AF XY:
AC XY:
85580
AN XY:
130476
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.645 AC: 893038AN: 1384796Hom.: 290990 Cov.: 21 AF XY: 0.649 AC XY: 449597AN XY: 692990
GnomAD4 exome
AF:
AC:
893038
AN:
1384796
Hom.:
Cov.:
21
AF XY:
AC XY:
449597
AN XY:
692990
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.618 AC: 93931AN: 152010Hom.: 29395 Cov.: 32 AF XY: 0.621 AC XY: 46111AN XY: 74300
GnomAD4 genome
AF:
AC:
93931
AN:
152010
Hom.:
Cov.:
32
AF XY:
AC XY:
46111
AN XY:
74300
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2621
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 03, 2015 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Tyrosinemia type I Benign:2
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 01, 2021 | - - |
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Jul 26, 2019 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at